Ragweed pollen-specific IgG

Ragweed pollen-specific IgG refers to immunoglobulin G antibodies produced against allergens in ragweed (Ambrosia artemisiifolia) pollen, primarily in response to allergen-specific immunotherapy (AIT) for ragweed allergy. These antibodies, particularly IgG4 subclasses, act as blocking antibodies by competing with pathogenic IgE for binding to major ragweed allergens like Amb a 1, thereby inhibiting IgE-facilitated antigen presentation to T cells and reducing seasonal rises in allergen-specific IgE levels. In ragweed pollen-allergic patients, who often experience severe symptoms such as rhinitis, conjunctivitis, asthma-like symptoms, and skin reactions upon exposure, elevated ragweed-specific IgG levels correlate with protection during AIT and help distinguish genuine ragweed sensitization from cross-reactivity with pan-allergens like profilins (Amb a 8). While Amb a 1-specific IgE dominates in most patients (accounting for >50% of total ragweed-specific IgE), IgG responses emerge post-AIT to modulate the Th2-skewed immune response characteristic of allergy. Quantification of these IgG levels, alongside subclasses like IgG2 and IgG3, aids in assessing treatment success and personalizing AIT, though subclass distributions show high inter-individual variability. No direct small-molecule drugs target this immune response; instead, therapeutic strategies rely on ragweed pollen extracts or engineered hypoallergenic vaccines to induce protective IgG without excessive IgE side effects.

Other names

Ragweed-specific IgGAmbrosia artemisiifolia pollen-specific IgG

Blocking IgE-allergen complex formation, Competition with IgE for allergen binding, Inhibition of seasonal IgE rise, Reduction of effector cell responses